These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37061248)

  • 21. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    García-Alfonso P; García-Foncillas J; Salazar R; Pérez-Segura P; García-Carbonero R; Musulén-Palet E; Cuatrecasas M; Landolfi S; Ramón Y Cajal S; Navarro S; ;
    Clin Transl Oncol; 2015 Apr; 17(4):264-73. PubMed ID: 25373533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia.
    Mitsudomi T; Tan D; Yang JC; Ahn MJ; Batra U; Cho BC; Cornelio G; Lim T; Mok T; Prabhash K; Reungwetwattana T; Ren SX; Singh N; Toyooka S; Wu YL; Yang PC; Yatabe Y
    J Thorac Oncol; 2023 Apr; 18(4):436-446. PubMed ID: 36379356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
    Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
    Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):539-574. PubMed ID: 37460438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).
    García-Alfonso P; Salazar R; García-Foncillas J; Musulén E; García-Carbonero R; Payá A; Pérez-Segura P; Ramón y Cajal S; Navarro S; ;
    Clin Transl Oncol; 2012 Oct; 14(10):726-39. PubMed ID: 22855150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic and predictive biomarkers in non-small cell lung carcinoma.
    Odintsov I; Sholl LM
    Pathology; 2024 Mar; 56(2):192-204. PubMed ID: 38199926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
    Ekin Z; Nart D; Savaş P; Veral A
    Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.
    Vavala T; Malapelle U; Veggiani C; Ludovini V; Papotti M; Leone A; Graziano P; Minari R; Bono F; Sapino A; Manotti L; Troncone G; Pisapia P; Girlando S; Buffoni L; Righi L; Colantonio I; Bertetto O; Novello S
    J Clin Pathol; 2022 Apr; 75(4):234-240. PubMed ID: 33509945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
    Provencio M; Cobo M; Rodriguez-Abreu D; Calvo V; Carcereny E; Cantero A; Bernabé R; Benitez G; Castro RL; Massutí B; Del Barco E; García Campelo R; Guirado M; Camps C; Ortega AL; González Larriba JL; Sánchez A; Casal J; Sala MA; Juan-Vidal O; Bosch-Barrera J; Oramas J; Dómine M; Trigo JM; Blanco R; Calzas J; Morilla I; Padilla A; Pimentao J; Sousa PA; Torrente M
    BMC Cancer; 2022 Jul; 22(1):732. PubMed ID: 35790916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updates in the molecular pathology of non-small cell lung cancer.
    Paver E; O'Toole S; Cheng XM; Mahar A; Cooper WA
    Semin Diagn Pathol; 2021 Sep; 38(5):54-61. PubMed ID: 33985831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
    Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
    J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
    Trigo J; García-Cosío M; García-Castaño A; Gomà M; Mesia-Nin R; Ruiz-Bravo E; Soria-Rivas A; Castillo P; Braña-García I; Alberola-Ferranti M
    Clin Transl Oncol; 2022 Oct; 24(10):1890-1902. PubMed ID: 35739348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Precision medicine in non-small cell lung cancer: Current applications and future directions.
    Yang SR; Schultheis AM; Yu H; Mandelker D; Ladanyi M; Büttner R
    Semin Cancer Biol; 2022 Sep; 84():184-198. PubMed ID: 32730814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.
    Sireci AN; Krein PM; Hess LM; Khan T; Willey J; Ayars M; Deyoung K; Bhaskar S; Mumuney G; Coutinho A
    Clin Lung Cancer; 2023 Jul; 24(5):429-436. PubMed ID: 37080814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.
    Brisudova A; Skarda J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):127-132. PubMed ID: 32284620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology.
    Marchetti A; Ardizzoni A; Papotti M; Crinò L; Rossi G; Gridelli C; Barberis M; Maiorano E; Normanno N; Taddei GL; Scagliotti G; Clemente C; Pinto C
    J Thorac Oncol; 2013 Mar; 8(3):352-8. PubMed ID: 23407559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: A Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
    Pérez JMT; García-Cosío M; García-Castaño A; Gomà M; Mesia-Nin R; Ruiz-Bravo E; Soria-Rivas A; Castillo P; Braña-García I; Alberola-Ferranti M
    Rev Esp Patol; 2023; 56(1):45-57. PubMed ID: 36599600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
    Rojo F; Conde E; Torres H; Cabezón-Gutiérrez L; Bautista D; Ramos I; Carcedo D; Arrabal N; García JF; Galán R; Nadal E
    BMC Cancer; 2022 Mar; 22(1):292. PubMed ID: 35303812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.